Published: Jan 17, 2026, 15:36 IST | Updated: Jan 17, 2026, 15:36 IST
NHS England will roll out the affordable prostate cancer drug abiraterone to thousands of high-risk patients, following landmark ICR research showing two years of treatment halves relapse risk and significantly cuts early death rates.